DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination-Reference-Cited by-同舟云学术

DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination

Published:2019-08-23 Issue:5 Volume:21 Page:397-408
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Syed Yahiya Y.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology, and Child Health

Link

http://link.springer.com/content/pdf/10.1007/s40272-019-00353-7.pdf

Reference50 articles.

1. Obando-Pacheco P, Rivero-Calle I, Gomez-Rial J, et al. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485–94.

2. Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Expert Rev Vaccines. 2016;15(12):1575–82.

3. European Medicines Agency. Hexyon suspension for injection: summary of product characteristics. 2013. https://www.ema.europa.eu . Accessed 10 Jun 2019.

4. McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Paediatr Drugs. 2013;15(1):59–70.

5. Madhi SA, Lopez P, Zambrano B, et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2018;15(3):658–68.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review;Vaccines;2024-09-01

2. Estimación del presupuesto de vacunas del PAI-Paraguay 2007-2022 y el impacto de posibles cambios;Revista Médica del Uruguay;2024-06-27

3. A worldwide overview for hexavalent vaccines and a glimpse into Turkiye’s perspective;Human Vaccines & Immunotherapeutics;2024-05-23

4. Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China;Human Vaccines & Immunotherapeutics;2024-04-15

5. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines;Inflammopharmacology;2024-02-03